Quarterly ResultMay 12, 2026, 07:37 AM
Mereo BioPharma Q1 Net Loss $6.7M; Setrusumab Regulatory Path Explored
AI Summary
Mereo BioPharma reported a reduced net loss of $6.7 million for Q1 2026, down from $12.9 million in Q1 2025. The company and its partner Ultragenyx are engaging regulatory agencies to determine a path forward for setrusumab in pediatric osteogenesis imperfecta, despite Phase 3 studies not meeting primary endpoints but showing significant improvements in secondary endpoints. Mereo is also actively seeking partners for alvelestat's Phase 3 development and expects its cash of $36.2 million to fund operations into mid-2027.
Key Highlights
- Q1 2026 net loss significantly reduced to $6.7 million from $12.9 million YoY.
- Cash and cash equivalents totaled $36.2 million as of March 31, 2026.
- Company expects existing cash to fund operations into mid-2027.
- Setrusumab: Engaging regulatory agencies for pediatric path despite Phase 3 primary endpoint miss.
- Alvelestat: Actively discussing with potential partners for Phase 3 development.
- Vantictumab: Partner āshibio to initiate Phase 2 trial in H2 2026.
- Q1 R&D expenses increased to $4.7 million, up $0.8 million YoY.
- Q1 G&A expenses decreased to $4.0 million, down $3.3 million YoY.
Price Impact
More from MREO